KRAS mutant NSCLC | ORR | DCR | ||||
---|---|---|---|---|---|---|
Chemotherapy | Immunotherapy | P value | Chemotherapy | Immunotherapy | P value | |
Overall | 30.43% (36/165) | 44.00% | 0.893 | 80.00% | 96.00% | 0.439 |
KRAS mutant subtypes | ||||||
 G12C | 29.63% | 54.17% | 0.667 | 81.48% | 95.83% | 0.924 |
 non-G12C | 30.12% | 34.62% | 0.654 | 78.31% | 92.31% | 0.679 |
PD-L1 expression | ||||||
  < 1% | 15.38% | 20.00% | 0.686 | 84.62% | 100.00% | 0.911 |
  ≥ 1% | 48.28% | 47.50% | 0.979 | 89.66% | 95.00% | 0.724 |